Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jazz Pharmaceuticals plc JAZZ

Healthcare
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn... see more

Recent & Breaking News (NDAQ:JAZZ)

Jazz Pharmaceuticals Announces Third Quarter 2020 Financial Results

PR Newswire November 2, 2020

Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program

PR Newswire October 26, 2020

Jazz Pharmaceuticals Announces SLEEP Publication of Phase 3 Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Study in Cataplexy or Excessive Daytime Sleepiness in Patients with Narcolepsy

PR Newswire October 20, 2020

Jazz Pharmaceuticals Announces Webcast for Xywav Investor Update

PR Newswire October 19, 2020

Jazz Pharmaceuticals to Report 2020 Third Quarter Financial Results on November 2, 2020

PR Newswire October 19, 2020

New Data for Zepzelca(TM) (lurbinectedin) to be Presented at IASLC 2020 North America Conference on Lung Cancer

PR Newswire October 14, 2020

Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia

PR Newswire October 8, 2020

Jazz Pharmaceuticals Launches Initiative to Help Educate People Living with Rare Form of Leukemia

PR Newswire September 17, 2020

Jazz Pharmaceuticals Announces New Sleep Health Collaboration

PR Newswire September 15, 2020

Jazz Pharmaceuticals Announces New Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer Therapies

PR Newswire September 9, 2020

Jazz Pharmaceuticals Announces Participation at Three Upcoming Virtual Investor Conferences

PR Newswire September 8, 2020

Etsy, Teradyne and Catalent Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

PR Newswire September 4, 2020

Jazz Pharmaceuticals to Present New Data on Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Sunosi® (solriamfetol) at Virtual SLEEP 2020

PR Newswire August 27, 2020

Jazz Pharmaceuticals Announces Second Quarter 2020 Financial Results

PR Newswire August 4, 2020

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy

PR Newswire July 22, 2020

Jazz Pharmaceuticals to Report 2020 Second Quarter Financial Results on August 4, 2020

PR Newswire July 21, 2020

National Comprehensive Cancer Network® adds Zepzelca(TM) (lurbinectedin) to Clinical Practice Guidelines in Oncology

PR Newswire July 13, 2020

Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca(TM) (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer

PR Newswire June 15, 2020

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 2.000% Exchangeable Senior Notes due 2026

PR Newswire June 9, 2020

Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2026

PR Newswire June 8, 2020